- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1684 |
Product Name |
ADT1684-Ustekinumab Biosimilar-Anti-Human IL-12 IL-23 mAb-Research Grade |
Alternate Names |
anti-mouse IL12B antibody, anti-IL12B antibody, anti IL12B antibody, recombinant IL12B, IL12B antibody, anti-IL12B monoclonal antibody, IL12B antibodies, IL12B recombinant antibody, IL12B blocking antibody |
Alias |
CNTO 1275, TT-20 |
Clonity |
Monoclonal |
Host |
CHO Cells |
Species |
Human |
Target |
IL12B |
Gene ID |
3593 |
Isotype |
IgG1 Kappa |
Size |
1mg, 5mg |
Research Area |
Immunology |
CAS Number |
815610-63-0 |
Chemical Formula |
C6482H10004N1712O2016S46 |
Product Description |
Ustekinumab, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23. |
Mechanism of Action |
Interleukin (IL)-12 and IL-23 are heterodimeric cytokines that evoke immune and inflammatory responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. The role of IL-12 and IL-23 were implicated in a variety of chronic inflammatory conditions, such as psoriasis and inflammatory bowel diseases. They modulate lymphocyte function, including T-helper (Th) 1 and Th17 cell subsets, as CD4+ T cells can differentiate into T-helper (Th) effector lineages based on the environment. Th cells can further activate the downstream pro-inflammatory mediators and transcription factors such as TNFα and IFNγ that drive innate and adaptive immunity.
IL-12 and IL-23 share a common p40 subunit, paired with p35 and p19 subunits of IL-12 and IL-23, respectively. The antigen-binding fragment (Fab) of ustekinumab binds the D1 domain of the p40 subunit of IL-12 and IL-23 in a 1:1 ratio. This prevents IL-12 and IL-23 from binding to the IL-12Rβ1 receptor chain of IL-12 (IL-12Rβ1/β2) and IL-23 (IL-12Rβ1/23R) receptor complexes on the surface of NK and T cells. Ustekinumab only binds to IL-12 and IL-23 that are unbound to IL-12Rβ1, so it is unlikely to initiate Fc effector functions, such as ADCC or CDC. Inhibitionition of the IL-12/23 signalling pathway leads to profound suppression of both the Th1 and Th17 cell lineage of cytokines and chemokines and their inflammatory pathways.
|
Metabolism |
The metabolic pathway of ustekinumab has not been fully characterized; it is expected to undergo nonspecific protein degradation via catabolic pathways in the same manner as endogenous IgG. |
Molecular Weight |
145.65 KDa |
Application |
Functional assay, IF, Neut, ELISA, FC |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reactivity |
Human |
|
Reference 1. Jahantigh D, et al. Cytokine, 2023 Apr. PMID 36842370
2. Ali Imarah A, et al. Arch Razi Inst, 2022 Feb. PMID 35891724
3. Wegeberg AM, et al. Cardiovasc Diabetol, 2022 Jan 6. PMID 34991588
|